Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
judging by the volume the last few minutes it feels like we're going to turn a corner today
They're talking about Jefferies on CNBC right now and my ears nearly shot off my head as they perked to hear if HGEN was going to get a namedrop.
... in due time *fingers crossed*.
*BUYERS BEWARE!* - Artificial Price Action?
As someone who was studying IZEA and their SEC filings this past Saturday in anticipation of opening a position this week, I came across some interesting excerpts from the most recent 10-Q that led me here to urge my peers that the price action this week smells and feels fraudulent/artificial.
I understand that the "Fortune 500 client" news coincided with the price jump... but who are these new clients/partners, and isn't it suspicious that that news broke to justify the stock price doubling above $1.00 the same day as a soft deadline for continued NASDAQ listing? At the very least, this probably has Short Sellers foaming at the mouth.
---
From P. 37 of the 10-Q for period ending March 31, 2020:
SEC Form 10-Q for IZEA
Aww thanks buddy :)
The price action was throwing me off last week but now it's pretty clear that JPM & friends are ratcheting up until this takes off. MWM called it sooner than I did.
Ever since this jumped $1 last week to build a cushion, JPM & friends are moving up 0.25-0.50 at a time, buying up to clear the shares at each price level.
I expect them to continue marching in this phalanx, clearing out loose shares along the way until compassionate use data news is published and the mainstream/retail investors file in.
They're swallowing these levels whole when they decide to ratchet up.
up up we go, CDEL ratcheting up with 10k bid at $3.76!
you're correct! I believe it was 10 days max though
Calm before the storm.... The rest of the market is red, traders will be taking money out of the FANGS and blue chips and putting it into <$10 stocks today... HGEN buyers lurking waiting for a dip to buy. a few 1k bids in the chamber right now, things will speed up into the day for sure.
*Disclaimer*... or not, who knows.
jeez who sold 20k @ $3.10? I don't even know where to begin on tryin to explain intraday price action on this stock.
Kite/Gilead & HGEN announce Lenz collaboration
Not on COVID19 but it shows the intimate partnership on the same drug and affinity to make a cocktail of the two... will be leveraged nicely as a comp for the COVID19 application to bolster confidence in that solution when the news breaks... just a matter of time now.
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
http://investors.gilead.com/news-releases/news-release-details/kite-and-humanigen-announce-clinical-collaboration-evaluate
GTSM didnt even flinch! picked up 8k @ 3.27 and reloaded for 13k more at $3.28.... big money coming in HOT.
GTSM has entered the game.
Laying down with a bid at $3.27 for 8k... Haven't seen them play hard on Level2 until today... Looks like someone in Taiwan wants in on the action.
Great homework! Thanks for keeping the landscape updated.
20k shares purchased at $3.30! ... Heavy hands clearing the way.
OTCX matching CDEL's buying power today so far.... word seems to have finally hit the street on HGEN.
WOW, swallowed up the 10k asks at $3.10 like it was nothing.
Here's some of my DD to help speed anyone up still looking to open a position:
Background
- Based in South San Francisco
- <20 Employees
- Takeover by Martin Shrkeli (aka "Pharma Bro") Nov '15
- Filed Chapter 11 Dec '15
- Changed name from "KalioBios" to "Humanigen" shortly after
- Has never brought a product to market
- Lenzilumab has been the primary focus of the company for last 2yrs
Financials
-SEC Filing - HGEN - Quarterly Report (Form 10-Q) - https://www.sec.gov/Archives/edgar/data/1293310/000121465920004718/j5820210q.htm
-Liquidity & Going Concern (Excerpt from Quarterly Report)
"The Company has incurred significant losses since its inception in March 2000 and had an accumulated deficit of $287.4 million as of March 31, 2020. At March 31, 2020, the Company had a working capital deficit of $15.1 million. To date, none of the Company’s product candidates has been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses to continue for the foreseeable future. The Company will require additional financing in order to meet its anticipated cash flow needs, which are expected to increase as the Company’s clinical trial activities accelerate during the next twelve months. As a result, the Company will continue to require additional capital through equity offerings, debt financing and/or payments under new or existing licensing or collaboration agreements. If sufficient funds are not available on acceptable terms when needed, the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern."
Product
- Focused on developing medicine for patients with neglected & rare diseases.
- Lenzilumab
- A humanized monoclonal antibody that targets GM-CSF
Application:
- Immune response to infection releases cytokines into the bloodstream to fight the disease
- Some patients have a deranged response where excessive cytokines flood the bloodstream
- This cytokine causes a "storm" which causes severe inflammation, compounding existing respiratory complications.
- Lenzilumab blocks the cell communication for GM-CSF, reducing sensitivity of cytokine release, preventing "cytokine storm"
- Video Explanation
Hasn’t made a single dollar off drug sales but the EPS has improved from -$9 to -$.09 over the last 5yrs (if I recall correctly off the top of my head).... disciplined management and focus! They trimmed their focus to only a few projects to keep from hemorrhaging money on projects that might not be realized as effectively.
I have to believe having risen to being on the cusp of profitability was one of the significant factors in the PIPE this week.
All signals have HGEN poised for a breakout.... Product, fundamentals, financial backing, management, market.
$40 stock all day once it gets a little light shed on it.... Dale Chappelle’s “Dark Horse Capital” had it all in the name.... HGEN will have big documentaries on it in 1-2yrs.
25k shares purchased @ $2.80! did anyone catch who that was? @ 3:33p
Thank you!
CDEL leading the charge!
I have to say when I saw the 8-K mention a max 10day blackout period for the 71M equity, my immediate thought was "oh F-, I've got to get out of this now" because my mind went to the same place.
Looking at the situation as a black-box, I would be exiting.
However, the discipline of management and quality of science HGEN has exercised over the last 2 months is, I believe, reflected in the prestige of not only the hospitals that welcomed the study, but in the financial backing they garnered as well.
Both the science and financial institutions HGEN's work has attracted leads me to believe that this is a genuine high-quality play and that the main parties believe in the the product & business, for the long haul.
Anything less in terms of quality and I'd be standing at the water's edge ready to jump out too.
All that said... i'm fairly new to this so my lesson may be just around the corner.
Yeah I share your sentiments... Based on the company movement and investment (not to mention WHO invested) and lack of short action (hasn't budged at all as far as i can tell in the last week)... these last few days feel like the calm before the storm with everyone try to load up on shares.
It's this kind of thinking that can get people in big losses, i recognize that fully... but everything about this gives me the feeling that we're poised for the up & up.
that explains the suppression until close on Tue 6/02... but any ideas on what's been keeping the price down the last two days? other institutional investors & hedge funds trying to get in on the action publicly?
Sure no problem, I'm actually learning about all this as we go.. HGEN is becoming quite the learning exercise for me:
If you invest via Private Investment in Public Equity (PIPE), by law you cannot sell any of your shares from that deal until the company files resale registration with the SEC. For this particular agreement, the 8-K outlines 10 days (which I think is on the low side).
So... Since the investors have their money locked in for at least 10 days, they want to protect their investment over that period... meaning they're going to want to keep the price elevated so that buy the time they can buy their shares back, they've made the most they can make... It wouldn't make sense put put down $71M on something without being able to liquidate it unless you know you're going to get a solid return on it.
True, they could let the price drop to $.88 and still make a profit of $2M... but smart money operates on a different order of magnitude... Not sure where they draw their line, but it won't be much below where we are now.
My guess is over the next few days you may see a lot of small investors like ourselves getting spooked and selling, or other public institutional investors trying to get in on the action by selling to drive the price lower to get a better buy-in price, but JPM & co will be policing the sells to make sure it stays above where they feel comfortable.
I'm so stoked on this news.
For those of us that bought in <$1 we've got JPM & friends behind us.
At a purchase price of 0.87 for their $71M investment there is NO WAY they're letting the price fall to get close to that... This is fantastic news, so pumped.
Watch out for a sell off tomorrow, with JPM & friends running a blockade to capture all the shares they can to defend their investment.
This just got way more fun.
$0.87/share for the JP Morgan PIPE!
"The closing of the Private Placement occurred on June 2, 2020 (the “Closing Date”). At the closing, the Company issued and sold 82,528,718 shares of Common Stock (the “Shares”) at a purchase price of $0.87 per share, for aggregate gross proceeds of approximately $71.8 million. The purchase price represented a 7% discount from the volume weighted average price of the Common Stock over the prior 20 trading days ending May 29, 2020. Effective upon completion of the Private Placement, the Company has an aggregate of 208,931,973 shares of Common Stock outstanding."
https://www.sec.gov/Archives/edgar/data/1293310/000121465920005413/r642008k.htm
What is going on here? Not fully understanding this price action...
My guess is someone (NITE, ETRF) is blocking the rally to keep it low to line their pockets with more shares... but am I missing something else?
I feel like i'm wrong because if the goal was to collect shares, why else would there be such a large sell-off at the close?
HGEN Presentation now underway @ Jefferies healthcare conference
3pm ET... invite only investor conference... let's see what happens to the price over the next hour.
Current Bid 1,851 @ 2.99
Current Ask 100 @ 3.01
Game recognizes game! *cheers*
Agreed. The mechanism of how Lenz targets Cytokine storm and the application for COVID is one of the factors that makes it so appealing to me as an investment... You see the market as a whole trying to rally desperately but the hesitation stemming from the concern of a 2nd wave keep giving it fals-starts...
Lenz's ability to suppress inflammation (fingers crossed) would be addressing this obstacle directly by minimizing the exposure to an influx of patients into ICUs/ventilators should a 2nd wave hit...
Leads me to feel like Lenz's success serves as a gatekeeper for a stepwise improvement in the rate of recovery for the market.
... It all depends on what news comes out and what language the FDA/Fauci/etc use to describe the results and application... but as of right now my plan is to pull out my initial investment before we hit $10 to put that into something else, then play with the house's money and let it ride.... I can totally see this hitting $20 in the next 2 months, just all depends on the news and language of the FDA.
It would be a dream if CNBC started to highlight this, would send us rocketing... but i doubt it.. it's a small/micro cap company... even though they have SEC filings i don't think CNBC would want to touch it.... Especially with the history of HGEN & Martin Shrkeli and Cramer and that whole thing... CNBC will be the last to touch this stock/story, but got i hope i'm wrong about this.
I did! Yahoo's HGEN board doesn't offer anything of substance... it feels like their posters just overheard a conversation about HGEN 2min before posting, and about a week behind the news.
This board is a bit more technical with higher discussion rate.. it's no reddit but it definitely gets the job done. thanks for having me!
That interview is 3wks old but PRECISELY what triggered me to open a position in HGEN:
@ 1:38 in the video he mentions an interim analysis of the study halfway through the trial.
Exactly 2wks (halfway point) from the 1st patient receiving Lenz, SEC filings showed Dr. Durrant & another director buying common stock...
That gave me the nod to open a position, which I increased iteratively as news started to trickle in...
1. Contract manufacturing agreement
2. Mayo Clinic/Stanford recruiting patients
3. Short interest decreasing to 0.7%
4. Zero PR from Humanigen (not a pump a dump)
5. and then finally, last wed/thursday when the first big pocket bidder placed an order for 28k shares under the radar
- (28k shares @ $~0.90 when the trading was around $0.85)
6. *BONUS* Speaking @ Jeffrie, approx 1 day after the 1st patient's study will conclude
7. *BONUS* JP Morgan's pipe (hehe)
8. Not to mention the quarterly report showing an improvement to (0.9) EPS since being (9.0) a few years ago, bringing on Cheval Holdings in April, and so on and so forth.
... knew we were ready to rally then, but that video interview with Proactive was what started it all.
Sit back and enjoy the ride ladies & gents.
Reached out to Jefferies & Humanigen on Monday to get a link to the conference... no dice :'(
Jefferies says you have to be a client; suggested i reach out to the company
Humanigen just ignored me haha but fine by me, they have more important things to address this week.
Still here!! Glued to Level 2.... CDEL trying to stretch legs and rally but NITE doesn't want to have it.
**Spoiler Alert**
CDEL will win this one today.
Wonderful validation in an interview with Dr. Durrant!
Lots of big takeaways here; Great to finally hear from the man himself after piecing these things together over the last few weeks. :D
https://www.proactiveinvestors.com/companies/news/921076/humanigen-announces-718-million-dollars-in-financing-921076.html
hahahaha... I lol'd hard at this, thank you.